Melina Marmarelis, MD,
Healio spoke with Melina Marmarelis, MD, assistant professor of medicine at the University of Pennsylvania, about the treatment landscape in metastatic non-small cell lung cancer.
In this video series, Marmarelis discussed:
- Utilizing biomarker testing to guide treatment options;
- Benefits of immunotherapy;
- The “explosion” of targeted therapy options in metastatic NSCLC;
- New treatment options in the pipeline, including anti-TIGIT agents; and
- The innovation and thoughtfulness that the COVID-19 pandemic has required of providers.
Disclosure:
Marmarelis reports receiving research funding to her institution from AstraZeneca, Eli Lilly, and Merck; serving in a consulting role with Astra Zeneca, Boehringer Ingelheim, Blueprint Pharmaceuticals, Bristol Myers Squibb, Ikena, Janssen, Novocure, and Takeda; and holding stock in Bluebird Bio, Gilead Sciences, Johnson & Johnson, Merck, Pfizer and Portola Pharmaceuticals.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.